• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

The choice of whether to stop or continue ADHD medications during pregnancy and nursing is a difficult decision for women suffering from the condition. Little data exists about how long-term exposure to these drugs could affect the foetus.

A study recently published in Molecular Psychiatry shows that children exposed to ADHD medication in utero do not develop neurological conditions like hearing loss or impaired vision seizures, febrile seizures, or IQ impairment. The authors acknowledge that more high quality studies are needed.

Risk/Benefit Analysis

Women who are pregnant and taking ADHD medications must weigh the benefits of using them against the risks to the foetus. Physicians don't have the data to provide clear recommendations however they can provide information on risks and benefits to help pregnant women make an informed decision.

A study published in Molecular Psychiatry concluded that women who were taking ADHD medication during early pregnancy did not have a greater risk of fetal malformations or structural birth defects. The researchers used a large population-based case-control study to assess the risk of major structural birth defects in infants born to mothers who had taken stimulants during early pregnancy, and those who did not. Clinical geneticists, pediatric cardiologists and other experts reviewed the cases in order to ensure that the classification was accurate and to eliminate any bias.

The study of the researchers was not without limitations. Most important, they were not able to differentiate the effects of the medication from the disorder at hand. This limitation makes it difficult to know whether the small differences observed in the exposed groups are due to the use of medication or confounding by comorbidities. The researchers also did not look at long-term outcomes for offspring.

The study revealed that infants whose mother had taken ADHD medication during pregnancy had a slightly greater risk types of adhd medication being admitted to the neonatal care unit (NICU), compared to mothers who didn't take any medication during pregnancy or had stopped taking their medication before or during pregnancy. The reason for this was central nervous system disorders. The higher risk of admission was not affected by the stimulant medication that was used during pregnancy.

Women who took stimulant ADHD medications during pregnancy also had a higher chance of having to have a caesarean section or the baby was not scoring well on the Apgar scale (less than 7). These increases appeared to be unrelated to the type of medication taken during pregnancy.

Researchers suggest that the small risks posed by the use of uk adhd medication medication during pregnancies in the early stages could be offset by the greater benefits to both mother and baby from continuing treatment for the woman’s disorder. Physicians should discuss the issue with their patients and, where they are able, assist them in developing strategies to improve their coping abilities which can reduce the negative impact of her condition on her daily functioning and relationships.

Medication Interactions

As more women than ever before are being diagnosed with ADHD and treated with medication, the dilemma of whether or not to stop treatment during pregnancy is a question that doctors are having to confront. These decisions are usually made without clear and authoritative evidence. Instead, physicians must consider their own expertise, the experience of other physicians and the research on the topic.

The issue of possible risks for infants can be extremely difficult. The research that has been conducted on this topic is based on observations rather than controlled studies and a lot of the results are conflicting. The majority of studies focus on live births, which can underestimate the teratogenic impact which can cause abortions or terminations of pregnancy. The study that is discussed in this journal club addresses these shortcomings by looking at data from both live and deceased births.

The conclusion is that while certain studies have demonstrated a positive association between ADHD medications and the risk of certain birth defects, other studies have not found any evidence of a link, and most studies have a neutral or slightly negative effect. In each case an in-depth study of the potential risks and benefits must be performed.

For women suffering from ADHD and ADD, the decision to stop taking medication can be difficult, if not impossible. In fact, in an article published in Archives of Women's Mental Health, psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can lead to increased depression, feelings of loneliness, and family conflict for these patients. The loss of medication can also affect the ability to drive safely and to perform work-related tasks which are crucial aspects of normal life for people with ADHD.

She recommends that women who are unsure about whether to continue or stop medication in light of their pregnancy should consider educating family members, friends and colleagues about the condition, its effects on daily life, and the advantages of staying on the current treatment regimen. It can also help a woman feel more confident in her decision. Certain medications can be passed through the placenta. If a woman decides to not take her ADHD best medication for adhd combined type while pregnant and breastfeeding, it's important to be aware that the medication may be transferred to her baby.

Birth Defects and Risk of

As the use and misuse of adhd medication for adults uk medication to treat symptoms of attention deficit hyperactivity disorder (ADHD) increases, so does concern about the potential effects of these drugs on the fetuses. Recent research published in the journal Molecular Psychiatry has added to the body of knowledge on this issue. Researchers used two massive data sets to study more than 4.3 million pregnancies and determine if stimulant medication use caused birth defects. Researchers discovered that although the risk overall is low, the first trimester ADHD exposure to medication was associated with slightly higher rates of specific heart defects like ventriculoseptal defects.

The researchers behind the study found no link between early medication use and congenital abnormalities such as facial clefting or club foot. The findings are in line with previous studies revealing the presence of a small, but significant increase in the risk of heart malformations among women who started taking ADHD medications prior to the time of pregnancy. This risk increased during the latter half of pregnancy, when a lot of women began to stop taking their medication.

Women who used ADHD medications in the first trimester of pregnancy were also more likely to undergo caesarean section, low Apgar score after delivery and a baby who needed help breathing at birth. The researchers of the study could not remove bias in selection since they restricted the study to women without other medical conditions that could have contributed to the findings.

The researchers hope their research will aid in the clinical decisions of physicians who treat pregnant women. They advise that while a discussion of the risks and benefits is crucial however, the decision to stop or continue treatment should be based on the woman's needs and the severity of her ADHD symptoms.

The authors warn that, although stopping the medication is a possibility to consider, it is not recommended because of the high incidence of depression and mental health issues in women who are expecting or have recently given birth. Additionally, research suggests that women who stop taking their medication will have a tough time adjusting to a life without them once the baby is born.

Nursing

It can be overwhelming becoming a mother. Women who suffer from ADHD who have to deal with their symptoms while attending physician appointments as well as getting ready for the arrival of a baby and adapting to new routines in the home can experience severe challenges. Therefore, many women elect to continue taking their ADHD medications throughout pregnancy.

The majority of stimulant drugs are absorbed by breast milk in low amounts, so the risk to the infant who is breastfeeding is low. However, the frequency of exposure to medications by the infant can differ based on dosage, frequency it is administered and the time of the day the medication is administered. In addition, different drugs enter the infant's system via the gastrointestinal tract, or through breast milk. The impact on a newborn's health is not completely understood.

Some doctors may decide to stop stimulant medications during a woman's pregnancy due to the lack of research. This is a difficult decision for the patient, who must weigh the benefits of continuing her medication against the possible risks to the embryo. As long as more information is available, GPs can inquire about pregnant patients if they have any background of ADHD or if they are planning to take medication in the perinatal stage.

Numerous studies have proven that women can continue to take their ADHD medication in a safe manner during pregnancy and breast-feeding. This has led to an increasing number of patients are choosing to do so and after consulting with their doctor, they have discovered that the benefits of maintaining their current medication far outweigh any risks.

It is crucial for women suffering from ADHD who are thinking of breastfeeding to seek out a specialist psychiatrist's guidance prior to becoming pregnant. They should discuss their medication with their doctor and discuss the advantages and disadvantages of continuing treatment, including non stimulant adhd medication uk-pharmacological management strategies. Psychoeducation should also be offered to help pregnant women suffering from ADHD recognize their symptoms and the underlying disorder, learn about available treatments and to reinforce existing strategies for coping. This should be a multidisciplinary approach including obstetricians, GPs and psychiatry. Pregnancy counseling should include discussion of a treatment plan for the mother as well as the child, and monitoring for signs of deterioration and, if necessary, adjustments to the medication regimen.